Hyperfine announced the U.S. Food and Drug Administration (FDA) 510(k) clearance and launch of the company’s upgraded AI-powered software. The most recently cleared Swoop software improves the image quality of the diffusion-weighting imaging sequence with increases in its signal-to-noise ratio. An additional update in this software release increases the Swoop Portable MR Imaging System field of view by 10% for T1, T2, and FLAIR sequences to match the previously improved DWI sequence’s 20cm field of view. Field of view size is important for visualizing pathology deep in the brain.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HYPR:
- Hyperfine, Inc. Announces FDA Clearance for Improved AI-Powered Software and Expanded Field of View for the Swoop® Portable MR Imaging® System
- Latest Data Demonstrate Potential of the Swoop® Portable MR Imaging® System in the Follow-up of Stroke Patients Who Have Received a Thrombectomy
- Hyperfine names Brett Hale chief administrative office, CFO
- Hyperfine, Inc. Announces Brett Hale as New Chief Administrative Officer & Chief Financial Officer
- Hyperfine Swoop® Point-of-Care MRI System™ Takes the Stage at ISMRM with Twelve Abstract Inclusions